A new study in Diabetes, Obesity and Metabolism found that many people with obesity stop taking GLP-1 drugs like semaglutide due to side effects, high cost, or limited access, despite their proven weight loss benefits. Only half stayed on treatment long-term, but those who did lost significantly more weight, showing the impact of continued use.